Everyday Health featured Adam Cloe, MD, FCAP, who explained how pathologists use highly sensitive testing methods to detect minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL). “MRD testing casts a finer net, capable of detecting one abnormal cell within a population of 10,000 and, in some cases, even one cell out of a million,” said Dr. Cloe.
For the full article click here: What Undetectable Minimal Residual Disease (uMRD) Means for Your CLL Prognosis